Venkat Nelabhotla

Co-Founder, President & CEO

Biotechnology therapies represent a transformative frontier in medicine, offering innovative treatments for a wide range of previously untreatable conditions. This cutting-edge field encompasses diverse approaches, including biologics, monoclonal antibodies, RNA-based therapies, and groundbreaking cell and gene therapies. By leveraging advanced biotechnological techniques, these therapies aim to repair, replace, or enhance biological functions, addressing conditions such as rare genetic disorders, cancers, autoimmune diseases, and degenerative conditions. The industry has experienced rapid growth, driven by technological advancements and the increasing approval of therapies like CAR-T, CRISPR-based treatments, and RNA-based drugs. The overarching significance of biotechnology therapies lies in their capacity to transform healthcare by delivering tailored treatments and addressing critical unmet medical needs.

Vyome Therapeutics, a clinical-stage biotechnology company based in Cambridge, Massachusetts, U.S., is uniquely positioned to create value through strategic drug repurposing. Headquartered in Cambridge MA, U.S., the company was founded by a team of distinguished business leaders and pioneering scientific experts, supported by a consortium of renowned investors who share a commitment to driving impactful innovation.

Since its inception, Vyome Therapeutics has seamlessly integrated scientific rigor, strategic business insight, and global execution capabilities to address unmet medical needs, with a particular focus on immuno-inflammatory and rare disease indications. The company’s operating model leverages the complementary strengths of the U.S. and India, combining cutting-edge innovation with capitalefficient development strategies.

Tackling High-Need Indications with Repurposed Science

Vyome Therapeutics' lead asset, VT-1953, is a groundbreaking fourth-generation antibiotic and antiinflammatory molecule with a distinct mechanism of action tailored to address polymicrobial environments. The flagship program targets malodor associated with malignant fungating wounds, a debilitating symptom significantly impacting the quality of life for patients with advanced malignancies. This indication represents a critical unmet need with the potential for orphan designation.

Preclinical research and Phase II Investigator Initiated clinical studies have demonstrated VT-1953’s efficacy in reducing malodor by neutralizing key pathogenic bacteria. Interim results reveal promising clinical benefits while maintaining a favorable safety profile, paving the way for progression into pivotal trials.

Additionally, Vyome Therapeutics is repurposing VT- 1953 to treat inflammatory acne, a prevalent immune inflammatory condition. The molecule has undergone rigorous evaluation in a Phase IIB trial in the USA involving over 400 patients. The data thus far underscores its efficacy and tolerability, aligning seamlessly with the company’s commitment to developing a scientifically validated pipeline.

Expanding its portfolio, Vyome Therapeutics is advancing a topical immunomodulator to treat steroid-incompatible uveitis. This program focuses on patients who cannot use topical corticosteroids due to contraindications or adverse effects. By repurposing a known immunomodulatory molecule with an established safety profile, the company aims to deliver a novel local treatment option for this underserved patient population.

Further showcasing its innovation, the company has developed the Molecular Replacement Therapeutics (MRT) platform, a patented technology that enhances the efficacy of existing topical antifungal agents. This platform has yielded two clinically tested products and led to the successful commercialization of three products in collaboration with Sun Pharma in India. MRT exemplifies Vyome Therapeutics' ability to translate robust R&D into tangible commercial success, validating its scientific platforms and market acumen.

“Our intellectual property strategy is a cornerstone of our competitive advantage at Vyome Therapeutics. We hold a comprehensive portfolio of patents that cover platform technologies, formulations, and methods of use across major global markets. This robust protection not only safeguards our innovations but also provides us with the flexibility to pursue strategic partnerships and diverse commercialization pathways”, emphasizes Venkat Nelabhotla, Co-Founder, President & CEO, Vyome Therapeutics.

Capital-Efficient Development Philosophy

Vyome Therapeutics' approach to drug repurposing extends beyond scientific innovation, it embodies a disciplined financial strategy. By focusing on molecules with well-established pharmacological and safety profiles, the company streamlines clinical development, mitigates regulatory uncertainty, and optimizes capital utilization. This strategic framework is designed to efficiently achieve critical inflection points, enabling maximum value creation while minimizing investment risks.

This philosophy is reflected in its choice of therapeutic areas, which strategically balance rare indications, leveraging opportunities for accelerated pathways and market exclusivity, with broader immuno-inflammatory conditions that present significant commercial potential.

Leveraging the U.S.–India Innovation Corridor

A cornerstone of Vyome Therapeutics' strategy is its seamless integration of U.S.-based strategic leadership, financing, and regulatory expertise with India’s strengths in CMC, preclinical research, and clinical operations. This U.S.–India innovation corridor enables the company to uphold the highest quality standards while achieving exceptional speed and cost-efficiency throughout the drug development lifecycle.

By harnessing the complementary strengths of these two ecosystems, Vyome Therapeutics has built a robust and sustainable pipeline, deploying capital strategically to maximize impact. This approach is particularly valuable in today’s dynamic biotech landscape, where agility and costeffectiveness are paramount.

Poised at an exciting inflection point, the company is advancing its pipeline into pivotal stages of development, supported by a proven model of innovation and execution. With world-class leadership, scientific excellence, and a global operating strategy, Vyome Therapeutics is uniquely positioned to deliver transformative therapies for patients and create substantial value for its stakeholders.